Table 9.
Clinical evaluation outcome (success, failure, indeterminate) by indication
| Characteristic | cIAI (n = 90) |
cUTI (n = 103) |
HAP/VAP (n = 114) |
Other (n = 209)a |
Total (n = 516) |
|---|---|---|---|---|---|
| Overall outcome of ceftazidime–avibactam (any therapy), n (%) | |||||
| Treatment success | 58 (64.4) | 91 (88.3) | 78 (68.4) | 172 (82.3) | 399 (77.3) |
| Treatment failure | 18 (20.0) | 6 (5.8) | 14 (12.3) | 22 (10.5) | 60 (11.6) |
| Indeterminate | 14 (15.6) | 6 (5.8) | 22 (19.3) | 15 (7.2) | 57 (11.0) |
| Overall outcome by subgroups | |||||
| Ceftazidime–avibactam in monotherapy regimen, n (%) | |||||
| n | 26 | 68 | 25 | 39 | 158 |
| Treatment success | 17 (65.4) | 60 (88.2) | 17 (68.0) | 34 (87.2) | 128 (81.0) |
| Treatment failure | 7 (26.9) | 2 (2.9) | 4 (16.0) | 1 (2.6) | 14 (8.9) |
| Indeterminate | 2 (7.7) | 6 (8.8) | 4 (16.0) | 4 (10.3) | 16 (10.1) |
| Ceftazidime–avibactam in combination therapy regimens, n (%) | |||||
| n | 64 | 35 | 89 | 170 | 358 |
| Treatment success | 41 (64.1) | 31 (88.6) | 61 (68.5) | 138 (81.2) | 271 (75.7) |
| Treatment failure | 11 (17.2) | 4 (11.4) | 10 (11.2) | 21 (12.4) | 46 (12.8) |
| Indeterminate | 12 (18.8) | 0 (0.0) | 18 (20.2) | 11 (6.5) | 41 (11.5) |
| Patients treated in first line, n (%)b | |||||
| n | 18 | 31 | 15 | 62 | 126 |
| Treatment success | 12 (66.7) | 26 (83.9) | 11 (73.3) | 48 (77.4) | 97 (77.0) |
| Treatment failure | 3 (16.7) | 3 (9.7) | 2 (13.3) | 9 (14.5) | 17 (13.5) |
| Indeterminate | 3 (16.7) | 2 (6.5) | 2 (13.3) | 5 (8.1) | 12 (9.5) |
| Patients treated in second line, n (%)c | |||||
| n | 72 | 72 | 99 | 147 | 390 |
| Treatment success | 46 (63.9) | 65 (90.3) | 67 (67.7) | 124 (84.4) | 302 (77.4) |
| Treatment failure | 15 (20.8) | 3 (4.2) | 12 (12.1) | 13 (8.8) | 43 (11.0) |
| Indeterminate | 11 (15.3) | 4 (5.6) | 20 (20.2) | 10 (6.8) | 45 (11.5) |
| Immunocompromised patients, n (%)d | |||||
| n | 47 | 60 | 29 | 107 | 243 |
| Treatment success | 30 (63.8) | 57 (95.0) | 17 (58.6) | 87 (81.3) | 191 (78.6) |
| Treatment failure | 11 (23.4) | 3 (5.0) | 6 (20.7) | 14 (13.1) | 34 (14.0) |
| Indeterminate | 6 (12.8) | 0 (0.0) | 6 (20.7) | 6 (5.6) | 18 (7.4) |
| Non-immunocompromised patients, n (%) | |||||
| n | 43 | 43 | 85 | 102 | 273 |
| Treatment success | 28 (65.1) | 34 (79.1) | 61 (71.8) | 85 (83.3) | 208 (76.2) |
| Treatment failure | 7 (16.3) | 3 (7.0) | 8 (9.4) | 8 (7.8) | 26 (9.5) |
| Indeterminate | 8 (18.6) | 6 (14.0) | 16 (18.8) | 9 (8.8) | 39 (14.3) |
| Patients with daily dose < 4 ge | |||||
| n | 9 | 39 | 18 | 28 | 94 |
| Treatment success | 4 (44.4) | 35 (89.7) | 9 (50.0) | 21 (75.0) | 69 (73.4) |
| Treatment failure | 4 (44.4) | 3 (7.7) | 2 (11.1) | 3 (10.7) | 12 (12.8) |
| Indeterminate | 1 (11.1) | 1 (2.6) | 7 (38.9) | 4 (14.3) | 13 (13.8) |
| Patients with daily dose ≥ 4 g | |||||
| n | 81 | 64 | 96 | 181 | 422 |
| Treatment success | 54 (66.7) | 56 (87.5) | 69 (71.9) | 151 (83.4) | 330 (78.2) |
| Treatment failure | 14 (17.3) | 3 (4.7) | 12 (12.5) | 19 (10.5) | 48 (11.4) |
| Indeterminate | 13 (16.0) | 5 (7.8) | 15 (15.6) | 11 (6.1) | 44 (10.4) |
BSI bloodstream infection, cIAI complicated intra-abdominal infection, cUTI complicated urinary tract infection, HAP hospital-acquired pneumonia, VAP ventilator-associated pneumonia
aIncludes patients with BSI/sepsis
bPatients with no antibiotics for Gram-negative coverage before the start of ceftazidime–avibactam
cPatients with at least one antibiotic for Gram-negative coverage used for the same infection before the start of ceftazidime–avibactam
dPatients with underlying cancer (metastatic/non-metastatic), hematological malignancy/leukemia or lymphoma, bone marrow or solid organ transplantation, or acquired immunodeficiency syndrome (AIDS)
eDose adjustment due to renal impairment